Belite Bio, Inc (BLTE) has a MoatMap StockRank of 75/100 based on Quality (51/100), Value (37/100), and Momentum (66/100) factor scores. The current signal is BUY. Belite Bio, operating in the biotechnology sector, typically involves high R&D intensity, significant capital burn, binary outcomes, and a long, uncertain path to profitability. This speculative profile is antithetical to the Terry Smith and Warren Buffett lenses which seek proven quality compounders with durable moats, predictable cash flows, and rational capital allocation. No clear, unpriced macro tailwind for this specific biotech exists.
Belite Bio, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for retinal diseases. The company targets serious eye diseases with high unmet medical needs, such as Stargardt disease and dry Age-related Macular Degeneration (AMD), leveraging its proprietary drug candidates. Belite Bio is a specialized ophthalmology biotech firm, dedicated to advancing treatments for degenerative eye conditions.
| Price | $143.00 |
| Market Cap | $6.3B |
| P/E (Forward) | 193.59 |
| Price/Book | 7.76 |
| Return on Equity | -16.9% |
| Return on Invested Capital | -10.1% |
| Debt/Equity | 0.06 |
| Gross Margin | 0.0% |
| Operating Margin | 0.0% |
| Free Cash Flow | $-10M |
Belite Bio, Inc operates in the Biotechnology industry, part of the Healthcare sector (United States).